NDAORALTABLET
Approved
Jan 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANADROL-50 (oxymetholone) is an oral anabolic steroid approved in 1972 for treating specific hematologic and wasting conditions. The mechanism of action involves androgenic and anabolic effects that stimulate red blood cell production and protein synthesis. It is classified as a small molecule oral tablet.
LOE Approaching
Product approaching loss of exclusivity with modest competitive pressure (30), indicating a smaller, defensive brand team focused on maintaining legacy market share.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ANADROL-50 represents a legacy product in a defensive phase with limited job openings and modest career growth potential. Roles focus on maintaining market presence and managing the LOE transition rather than expansion and innovation.
Brand ManagerProduct Manager
Worked on ANADROL-50 at Pharmobedient? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.